GlassScriptPhysician profile
Marcelle A Grassi
NPI 1881690915
$10,434.80
in general payments reported to CMS, 2019-2025
30 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $1,030 · 2021: $1,143 · 2022: $1,842 · 2023: $1,971 · 2024: $1,441 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.01 |
| Education | $313.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,361.17 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,285.76 | 2019-2025 | |
| Lilly USA, LLC | $1,099.99 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $1,026.43 | 2019-2025 | |
| Genzyme Corporation | $915.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $857.43 | 2019-2025 | Dupixent |
| Pfizer INC. | $707.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $524.98 | 2022-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $343.28 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $323.20 | 2019-2024 | Ilumya |
| Dermavant Sciences, INC. | $301.76 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $266.25 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $234.93 | 2019-2025 | Bimzelx |
| Incyte Corporation | $189.83 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $130.12 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $128.48 | 2022 | |
| Janssen Scientific Affairs, LLC | $123.33 | 2019 | |
| Glaxosmithkline, LLC. | $102.78 | 2019 | |
| Bausch Health US, LLC | $96.97 | 2021-2024 | Siliq, Targretin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.59 | 2019-2023 | Targretin, Siliq |
| Celgene Corporation | $60.75 | 2019 | |
| Amgen INC. | $59.99 | 2022-2023 | Otezla |
| Vyne Pharmaceuticals INC. | $48.72 | 2020-2021 | |
| Organon LLC | $40.67 | 2025 | Vtama |
| Leo Pharma INC. | $34.16 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $25.03 | 2019 | |
| Therakos LLC | $21.75 | 2025 | Uvadex |
| Helsinn Therapeutics (U.S.), INC. | $17.45 | 2025 | Valchlor |
| Taro Pharmaceuticals USA, INC. | $14.81 | 2019 | |
| Prugen, INC. Pharmaceuticals | $8.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelle Grassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.